Health for all
As a science-led global healthcare company we have the opportunity to improve the health and well-being of millions of people around the world.
We are improving access to our products, irrespective of where people live or their ability to pay, and we are working to control or eliminate diseases affecting the world’s most vulnerable people.
Access to healthcare
Improving access to healthcare is one of society’s most pressing challenges. We are actively seeking new ways of delivering healthcare and making our products more available and affordable to people who need them, wherever they live.
In developing countries, we offer specific medicines at prices, based on a country’s wealth and ability to pay, so that the poorest also have access to our treatments and vaccines. An example of this in the future is GSK’s vaccine against malaria, RTS,S.
For the past 30 years GSK has been working on developing a vaccine against malaria. This contagious disease kills between one and three million people each year in less privileged countries. A partnership with the MVI (Malaria Vaccine Initiative) was established in 2000 in order to develop a vaccine.
In July 2014, GSK has submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S. GSK has committed that the eventual price of RTS,S will cover the cost of manufacturing the vaccine together with a small return of around 5 per cent that will be reinvested in research and development for second-generation malaria vaccines, or vaccines against other neglected tropical diseases.
Working in partnership
GSK is also one of the main suppliers of medicines and vaccines to important international organisations. We work with UNICEF en GAVI in order to supply the medicines and vaccines globally so that the price is not a barrier to access. We also continue to support the WHO objective of eradicating polio by 2018 by providing vaccines to UNICEF until this is achieved.
Recognising our achievements in bringing access to healthcare, we have consistently ranked top in the Access to Medicines (ATM) Index since it began in 2008. The Index, published every two years, gives an independent assessment of pharmaceutical companies’ efforts to improve access. Our recent ranking as top of the 2016 ATM Index for the fifth time in a row reflects our long-term commitment to bringing access to healthcare across the world.
BE/COM/0010/15(2) Oct 2017